VLTR-559
Wet Age-Related Macular Degeneration (wet AMD)
Pre-clinicalActive
Key Facts
About Valitor
Valitor is a private, preclinical-stage biotech founded in 2020 and based in Cambridge, USA, focused on developing durable ophthalmic biologics. Its core technology involves conjugating bioactive molecules to a proprietary biopolymer to create multivalent drugs with extended therapeutic effect. The company is led by a seasoned team of ophthalmic and biotech executives and is advancing its lead candidate, VLTR-559, for wet age-related macular degeneration (AMD). Valitor's strategy is to build an efficient pipeline by applying its platform to validated targets in ocular diseases.
View full company profileTherapeutic Areas
Other Wet Age-Related Macular Degeneration (wet AMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| ONS-5010 / LYTENAVA™ (bevacizumab-vikg) | Outlook Therapeutics | Approved / BLA Resubmitted |